S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
New CBOE “special perk” helps traders target income every weekend (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China

Pasithea Therapeutics Stock Price, News & Analysis (NASDAQ:KTTA)

$0.32
-0.01 (-3.04%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.29
$0.32
50-Day Range
$0.30
$0.48
52-Week Range
$0.29
$1.05
Volume
32,350 shs
Average Volume
60,902 shs
Market Capitalization
$6.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Pasithea Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
527.0% Upside
$2.00 Price Target
Short Interest
Healthy
0.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Pasithea Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars


KTTA stock logo

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

KTTA Stock Price History

KTTA Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Pasithea Therapeutics Corp.
KTTA Pasithea Therapeutics Corp.
See More Headlines
Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/12/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KTTA
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+527.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-13,940,000.00
Pretax Margin
-3,436.96%

Debt

Sales & Book Value

Annual Sales
$490,000.00
Book Value
$1.36 per share

Miscellaneous

Free Float
17,899,000
Market Cap
$6.65 million
Optionable
Not Optionable
Beta
0.71
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Lawrence Steinman BA (Age 75)
    M.D., Ph.D., Executive Chairman & Co-Founder
    Comp: $250k
  • Dr. Tiago Reis Marques M.D. (Age 46)
    Ph.D., CEO & Director
    Comp: $539.25k
  • Mr. Daniel H. Schneiderman (Age 45)
    Chief Financial Officer
    Comp: $327.91k
  • Dr. Yassine Bendiabdallah Ph.D. (Age 38)
    COO & Head of UK Clinics
  • Dr. Graeme Currie Ph.D.
    Chief Development Officer














KTTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Pasithea Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pasithea Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KTTA shares.
View KTTA analyst ratings
or view top-rated stocks.

What is Pasithea Therapeutics' stock price target for 2024?

1 brokers have issued twelve-month price targets for Pasithea Therapeutics' stock. Their KTTA share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 527.0% from the stock's current price.
View analysts price targets for KTTA
or view top-rated stocks among Wall Street analysts.

How have KTTA shares performed in 2023?

Pasithea Therapeutics' stock was trading at $0.6417 at the beginning of the year. Since then, KTTA shares have decreased by 50.3% and is now trading at $0.3190.
View the best growth stocks for 2023 here
.

When is Pasithea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our KTTA earnings forecast
.

When did Pasithea Therapeutics IPO?

(KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KTTA) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -